Clinical trial
Rollover Study Of Lapatinib In Cancer Patients
NCT00169533 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00169533 |
|---|---|
| Title | Rollover Study Of Lapatinib In Cancer Patients |
| Official title | An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | GW572016 oral tablets |
| Enrollment | 31 |
| Start date | Aug 19, 2004 |
| Primary completion | May 5, 2009 |
| Completion | May 5, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 17, 2017 |
| Countries | Canada, Israel, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: